Objectives: This study aimed to analyze the serum levels of neopterin in patients with dermatomyositis (DM) in association with clinical manifestations, laboratory data and patient prognosis.

Methods: One hundred and eighty-two consecutive DM patients and 30 healthy controls were retrospectively enrolled in the study. Serum levels of neopterin were detected by using the ELISA method. Clinical and laboratory data and patient prognosis were obtained and analyzed in association with serum neopterin.

Results: Serum levels of neopterin were significantly increased in DM patients (median 21.2 nmol/L, IQR 13.9-35.2 nmol/L) compared to healthy controls (median 4.3 nmol/L, IQR 2.9-5.6 nmol/L, $P < 0.01$). High serum neopterin levels were associated with anti-MDA5 antibody, rapidly progressive interstitial lung disease (RP-ILD), and cutaneous involvement including skin ulcer and heliotrope rash. Longitudinal assessment of serum samples revealed that the serum neopterin levels were closely correlated with disease severity. In addition, a significant increase in serum neopterin concentration of non-survivors (median 38.7 nmol/L, IQR 23.5-65.3 nmol/L) was observed when compared to that of survivors (median 19.0 nmol/L, IQR 12.5-29.0 nmol/L) ($P < 0.01$). ROC curves showed that serum neopterin could distinguish non-survivors and survivors at an optimal cut-off level of 22.1 nmol/L with a sensitivity and specificity of 0.804 and 0.625 respectively ($P < 0.01$). Kaplan-Meier survival curves revealed that DM patients with serum neopterin > 22.1 nmol/L had a significantly higher mortality compared to patient group with serum neopterin < 22.1 nmol/L (logrank $P < 0.01$). Multivariate Cox regression analysis identified high serum neopterin concentration to be an independent risk factor for poor prognosis in DM (adjusted HR=4.619, 95%CI: 2.092-10.195, $P < 0.01$).

Conclusion: Increased serum levels of neopterin were significantly associated with RP-ILD and reduced survival in DM patients, suggesting it as a promising biomarker in the disease evaluation of DM. These findings highlight the role of cellular immune activation and macrophage activity in the pathogenesis of DM.

REFERENCE:

- [1] Murr C, Widner B, Wirlitner B, et al. Neopterin as a marker for immune system activation. *Current drug metabolism* 2002; 3: 175-87.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.784

FRIO309 SEVERE ABDOMINAL MANIFESTATIONS IN JUVENILE DERMATOMYOSITIS

Caroline Besnard¹, Cyril Gitiaux², Muriel Girard³, Louise Galmiche-Rolland⁴, Cécile Talbotec⁵, Pierre Quartier⁵, Laureline Berteloot⁶, Christine Bodemer⁷, Brigitte Bader-Meunier⁵. ¹Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM U 1163, Paris, France; ²Service de Neurophysiologie, Hôpital Necker, AP-HP, Paris, France; ³Unité de Gastroentérologie, Hépatologie et Nutrition pédiatrique, Hôpital Necker, AP-HP, Paris, France; ⁴Service d'Anatomo-Pathologie, Hôpital Necker, AP-HP, Paris, France; ⁵Service d'Immunologie, Hématologie et Rhumatologie Pédiatrique, Hôpital Necker, AP-HP, Paris, France; ⁶Service de Radiologie, Hôpital Necker, AP-HP, Paris, France; ⁷Service de Dermatologie et Dermatologie Pédiatrique, Hôpital Necker, AP-HP, Paris, France

Background: Juvenile dermatomyositis (JDM) is a rare and heterogeneous children-onset idiopathic inflammatory myopathy. It primarily affects skeletal muscle and skin, but also pulmonary, cardiac and gastrointestinal systems in a subset of patients. Gastrointestinal (GI) involvement occurs in 22 to 37% of JDM patients and have been described only in a few case reports.

Objectives: To describe causes of severe abdominal manifestations in JDM patients.

Methods: Retrospective monocentric study. Inclusion criteria were (i) diagnosis of JDM according to the modified Bohan and Peter criteria before 16 years of age, (ii) occurrence of severe involvement of any intra-abdominal organ, (iii) follow-up at Necker Hospital from 2005 to 2018. Severe abdominal manifestation was defined as a potential life-threatening abdominal organ event, need for abdominal surgery and/or parenteral nutrition. Gastrointestinal (GI) involvement was defined by severe abdominal pain, dysphagia, digestive hemorrhage, obstruction, ulceration and/or perforation. Severe hepatitis was defined by an elevation of liver enzymes exceeding five times the upper limit associated with an elevation of γ -glutamyl transferase (γ GT) activity and/or liver failure. Abdominal manifestations were classified as certain or probable primary JDM involvement, therapy-related event or infection-related event.

Results: Nine patients with 19 abdominal complications were identified among 110 JDM patients followed during the study period (8.3%).

Diagnosis of JDM was made at a median age of 10.7 years-old [range, 3.7 – 14.4], with a median CMAS of 7 [range, 2 – 48], median MMT of 47 [range, 38 – 76], a median creatine kinase level of 3 812 UI/L [range, 170 – 14 054], and a median follow-up of 3 years [range, 0.4 – 6.3]. Seven patients were positive for either anti-NXP2 ($n = 4$), anti-TIF1- γ ($n = 2$) or anti-MDA5 ($n = 1$) antibodies. JDM-related abdominal disease comprised GI involvement ($n = 10$), acute pancreatitis ($n = 4$) and hepatitis ($n = 3$). The revealing symptom for GI involvement and acute pancreatitis was abdominal pain. Five patients with severe abdominal pain, vomiting and/or obstruction, underwent abdominal imaging revealing thickening of colon ($n = 2$) and/or ileum mucosa ($n = 2$). Hepatitis was found in 3 patients with an uncommon extensive steatosis with moderate inflammation and perisinusoidal fibrosis ($n = 2$). Treatment-related complications were considered certain for methotrexate-induced liver toxicity (1 patient) and possible for duodenal perforations (1 patient) 3 days after a methylprednisolone pulse. At last visit, JDM was clinically inactive in four patients. Three patients died from refractory JDM, 2.9 years [range, 2 – 3.6] after the JDM diagnosis, among the 9 patients identified in this study *versus* only 1/92 of the other JDM patients from our cohort.

Conclusion: Primary JDM involvement was the main cause of severe abdominal manifestations and associated to a high mortality rate. We highlight for the first time that pancreatitis should be considered as a main diagnosis in JDM patients who develop severe and/or sustained abdominal pain.

Disclosure of Interests: Caroline Besnard: None declared, Cyril Gitiaux: None declared, Muriel Girard: None declared, Louise Galmiche-Rolland: None declared, Cécile Talbotec: None declared, Pierre Quartier Consultant for: AbbVie, Chugai-Roche, Lilly, Novartis, Novimmune, Sanofi, and SOBI, Consultant for: AbbVie, Chugai-Roche, Lilly, Novartis, Novimmune, Sanofi, and SOBI, Speakers bureau: AbbVie, BMS, Chugai-Roche, Novartis, Pfizer, and SOBI, Speakers bureau: AbbVie, BMS, Chugai-Roche, Novartis, Pfizer, and SOBI, Laureline Berteloot: None declared, Christine Bodemer: None declared, Brigitte Bader-Meunier: None declared

DOI: 10.1136/annrheumdis-2019-eular.3765

FRIO310 UNIVERSITY OF CALIFORNIA LOS ANGELES SCLERODERMA CLINICAL TRIALS CONSORTIUM GASTROINTESTINAL TRACT 2.0 REFLUX-SCALE ASSOCIATES WITH IMPAIRED ESOPHAGEAL SCINTIGRAPHY FINDINGS IN SYSTEMIC SCLEROSIS

Giuseppina Abignano^{1,2}, Gianna A. Mennillo¹, Antonio Carriero¹, Carmela Esposito^{1,3}, Angela Padula¹, Dinesh Khanna⁴, Salvatore D'angelo¹. ¹Rheumatology Institute of Lucania (IReL), Rheumatology Department of Lucania, Potenza, Italy; ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom; ³Rheumatology Division, Internal Medicine Department, Prato, Italy; ⁴University of Michigan, Department of Medicine, Ann Arbor, United States of America

Background: The University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA SCTC_GIT 2.0) questionnaire is a self-reported tool including 7-multi-item scales and measuring GI quality of life both in clinical trials and day-to-day clinic care of systemic sclerosis (SSc) patients (1). Scarce data are available on the correlation between patient reported GI symptoms and motility dysfunction as assessed by esophageal scintigraphy.

Objectives: To evaluate the UCLA SCTC_GIT 2.0 score in SSc patients undergoing esophageal scintigraphy and correlate their findings.

Methods: Data of SSc patients admitted to our clinic, undergoing esophageal scintigraphy, were reviewed. The score of UCLA SCTC_GIT 2.0, usually administered to all attending SSc patients, was calculated. Data were expressed as percentage (%) and mean $\pm$ standard error. Pearson's test was used for Prism 7 correlation analysis. $P < 0.05$ was considered significant.

Results: Of all the SSc patients admitted to our clinic from 1st Sept 2017 to 31st December 2018, twenty underwent esophageal scintigraphy. Seventeen were female, 4 with diffuse subset, mean age was 51 ($\pm$ 3.4) years, disease duration of 6.8 ($\pm$ 1.2 years) years. Twelve (60%) patients reported esophageal (reflux, dysphagia) symptoms, 5 (25%) stomach (early satiety, vomiting) and 9 (45%) intestinal (bloating, diarrhea, constipation) symptoms while 3 (15%) reported no symptoms. Mean $\pm$ SE scores of UCLA SCTC_GIT 2.0 items were: reflux 0.8 $\pm$ 0.2, distention 0.9 $\pm$ 0.2, fecal soiling 0.5 $\pm$ 0.2, diarrhea 0.5 $\pm$ 1, social 0.5 $\pm$ 0.1, emotional 0.5 $\pm$ 0.2, constipation 0.5 $\pm$ 0.1, and total UCLA SCTC_GIT 2.0 0.6 $\pm$ 0.1. Nine (45%) patients had no-mild, 4 (20%) moderate and 7 (35%) severe to very-severe reflux score. Esophageal scintigraphy showed hypomotility in 16 (80%) patients who had a higher UCLA SCTC_GIT 2.0 reflux score compared with the remaining 20% patients (1